CA3133620A1 - Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof - Google Patents
Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof Download PDFInfo
- Publication number
- CA3133620A1 CA3133620A1 CA3133620A CA3133620A CA3133620A1 CA 3133620 A1 CA3133620 A1 CA 3133620A1 CA 3133620 A CA3133620 A CA 3133620A CA 3133620 A CA3133620 A CA 3133620A CA 3133620 A1 CA3133620 A1 CA 3133620A1
- Authority
- CA
- Canada
- Prior art keywords
- abiraterone
- pharmaceutical formulation
- patient
- crystalline
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820076P | 2019-03-18 | 2019-03-18 | |
| US62/820,076 | 2019-03-18 | ||
| US201962942111P | 2019-11-30 | 2019-11-30 | |
| US62/942,111 | 2019-11-30 | ||
| PCT/US2020/023066 WO2020190900A1 (en) | 2019-03-18 | 2020-03-17 | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3133620A1 true CA3133620A1 (en) | 2020-09-24 |
Family
ID=72521270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3133620A Pending CA3133620A1 (en) | 2019-03-18 | 2020-03-17 | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220362264A1 (https=) |
| EP (1) | EP3941478A4 (https=) |
| JP (1) | JP2022525425A (https=) |
| CN (1) | CN113825514A (https=) |
| AU (1) | AU2020240017A1 (https=) |
| BR (1) | BR112021018540A2 (https=) |
| CA (1) | CA3133620A1 (https=) |
| IL (1) | IL286416A (https=) |
| WO (1) | WO2020190900A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022174134A1 (en) * | 2021-02-15 | 2022-08-18 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US12138273B2 (en) | 2019-03-06 | 2024-11-12 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101738369B1 (ko) * | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| EP3247334A1 (en) * | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
| WO2017037647A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical compositions of abiraterone |
| TWI717629B (zh) * | 2017-08-28 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cyp17抑制劑的藥物組合物及其製備方法 |
| WO2019060525A1 (en) * | 2017-09-22 | 2019-03-28 | Dispersol Technologies, Llc | PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF |
-
2020
- 2020-03-17 AU AU2020240017A patent/AU2020240017A1/en not_active Abandoned
- 2020-03-17 WO PCT/US2020/023066 patent/WO2020190900A1/en not_active Ceased
- 2020-03-17 BR BR112021018540A patent/BR112021018540A2/pt not_active IP Right Cessation
- 2020-03-17 JP JP2021556402A patent/JP2022525425A/ja active Pending
- 2020-03-17 CA CA3133620A patent/CA3133620A1/en active Pending
- 2020-03-17 US US17/437,144 patent/US20220362264A1/en not_active Abandoned
- 2020-03-17 EP EP20772679.5A patent/EP3941478A4/en not_active Withdrawn
- 2020-03-17 CN CN202080036072.5A patent/CN113825514A/zh active Pending
-
2021
- 2021-09-14 IL IL286416A patent/IL286416A/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12138273B2 (en) | 2019-03-06 | 2024-11-12 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| WO2022174134A1 (en) * | 2021-02-15 | 2022-08-18 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020240017A1 (en) | 2021-11-04 |
| US20220362264A1 (en) | 2022-11-17 |
| BR112021018540A2 (pt) | 2021-11-30 |
| WO2020190900A1 (en) | 2020-09-24 |
| EP3941478A1 (en) | 2022-01-26 |
| JP2022525425A (ja) | 2022-05-13 |
| IL286416A (en) | 2021-10-31 |
| EP3941478A4 (en) | 2022-12-28 |
| WO2020190900A8 (en) | 2021-10-14 |
| CN113825514A (zh) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021277731B2 (en) | Improved formulations of deferasirox and methods of making the same | |
| JP2023182674A (ja) | アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法 | |
| Kalia et al. | Solid dispersions: an approach towards enhancing dissolution rate | |
| Kumar et al. | Guargum and Eudragit® coated curcumin liquid solid tablets for colon specific drug delivery | |
| JP2010525082A (ja) | 固体投与形 | |
| EA027786B1 (ru) | Пероральные лекарственные формы бендамустина и их терапевтическое применение | |
| CN106265580A (zh) | Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂 | |
| CN107278152A (zh) | 醋酸阿比特龙复合物、其制备方法及包含它们的药物组合物 | |
| Narala et al. | Preparation and in vitro evaluation of hot-melt extruded pectin-based pellets containing ketoprofen for colon targeting | |
| US20220401579A1 (en) | Inclusion complexes of pharmaceuticals and cyclic oligomers | |
| KR20210151061A (ko) | 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형 | |
| US20220362264A1 (en) | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof | |
| TWI894266B (zh) | 醋酸阿比特龍和尼拉帕尼之藥物配製物 | |
| Choudhari et al. | Engineering Amorphous Solid Dispersions of Abiraterone Acetate via HPMC HME: A Polymer-Centric Hot-Melt Extrusion Strategy for Formulation-Driven Bioavailability Improvement. | |
| EA046804B1 (ru) | Форма соединения, обладающая повышенной биодоступностью, и ее составы | |
| EA053188B1 (ru) | Фармацевтические составы на основе абиратерона ацетата и нирапариба |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250903 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |